TransLabs Clients Hit 98% Clean Claims & 30% Faster AR Amid Rising Industry Denials

As payer denials climb across clinical and molecular laboratory billing nationwide, TransLabs client laboratories are moving in the opposite direction; posting clean claims and accounts receivable performance well ahead of industry benchmarks.

[Sachse, TX] — [August 10th, 2026] — TransLabs, a company that provides exclusive billing and coding services to clinical, reference, and molecular diagnostic laboratories, today announced that its client laboratories achieved an average clean claims rate of 98% and reduced average days in accounts receivable (AR) by 30% over the past twelve months; results that stand in sharp contrast to an industry grappling with rising claim denials.

The improvements come as payers across the diagnostics sector lean more heavily on automated claims review, expand prior-authorization requirements for molecular and genetic testing, and tighten documentation standards; a combination that has pushed denial rates upward for many independent and hospital-based laboratories over the past two years.

“Most labs are fighting the same problem: denials that used to be occasional are now a routine drain on cash flow,” said Kevin Pieterson, VP Sales at TransLabs. “Our clients are seeing the opposite trend because we built our process around catching the issues that cause denials before a claim ever goes out; eligibility gaps, missing authorizations, coding mismatches. A 98% clean claims rate isn’t luck. It’s the direct result of front-end discipline.”

TransLabs attributes the results to a combination of real-time eligibility verification, laboratory-specific coding audits, a continuously updated library of payer and LCD/NCD billing edits, and dedicated denial-analytics reporting that routes recurring issues back to the source; rather than treating each denial as an isolated event. The firm reports that clients who fully adopted this workflow saw AR days drop by an average of 30%, freeing up cash that would otherwise sit tied up in rework and appeals.

“Thirty percent faster AR isn’t just a billing metric; it’s working capital a lab can reinvest in staff, equipment, or growth,” said Oscar Shelby, Operations Manager at TransLabs. “When we bring on a new lab client, that’s usually the number that changes their financial picture the fastest.”

The announcement comes as denial management has become a top strategic concern for laboratory executives industry-wide, with many citing payer automation and expanding prior-authorization requirements as the primary drivers of rising denial volume. TransLabs said it will continue to publish quarterly performance benchmarks for its client base as part of an ongoing effort to bring more transparency to laboratory billing performance.

Laboratories interested in benchmarking their own clean claims rate and AR performance against industry standards can request a complimentary billing performance review through TransLabs.

About TransLabs

TransLabs is the nation’s leading laboratory billing and RCM company, built exclusively for clinical labs. Unlike generalist billing firms, we specialize solely in laboratory RCM — serving clinical, pathology, molecular diagnostic, toxicology, cytogenetics, genomics, and specialty labs nationwide. With a compliance-first approach, advanced automation, and dedicated account management, we help labs capture every dollar and eliminate revenue leakage generalists miss. We partner with labs of every size, from community hospital labs to large reference facilities, without workflow disruption. For more information, visit www.translabsbilling.com.